,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-10-29 23:25:00,We recently initiated coverage on Warner Chilcott plc ( WCRX ) with a Neutral recommendation and a target price of $13.00.,0.07264083623886108,0.006840591784566641,0.9205185174942017,neutral,0.065800242125988
1,2012-10-29 23:25:00,"Warner Chilcott, formed through multiple acquisitions and divestitures, is headquartered in Dublin, Ireland.",0.026128415018320084,0.007408714387565851,0.9664629101753235,neutral,0.01871970109641552
2,2012-10-29 23:25:00,"Warner Chilcott is a specialty pharmaceutical company engaged in developing, manufacturing, selling, and marketing branded prescription pharmaceutical products for women's healthcare, gastroenterology, dermatology and urology.",0.03509044274687767,0.005208615679293871,0.9597010016441345,neutral,0.029881827533245087
3,2012-10-29 23:25:00,"The women's healthcare franchise primarily caters to the hormonal contraceptive, osteoporosis and hormone therapy markets.",0.03398212045431137,0.0048057870008051395,0.9612120389938354,neutral,0.02917633391916752
4,2012-10-29 23:25:00,The primary products in the hormonal contraceptive sub-group include Loestrin 24 FE and Lo Loestrin FE.,0.021712180227041245,0.006595791783183813,0.9716920852661133,neutral,0.015116387978196144
5,2012-10-29 23:25:00,Actonel and its next generation version Atelvia are the primary osteoporosis drugs at Warner Chilcott.,0.030325524508953094,0.005782307591289282,0.9638921618461609,neutral,0.024543216452002525
6,2012-10-29 23:25:00,The drugs are marketed for the prevention and treatment of postmenopausal osteoporosis.,0.06546282768249512,0.008377134799957275,0.9261600971221924,neutral,0.05708569288253784
7,2012-10-29 23:25:00,"Estrace cream, approved for treating vaginal and vulvar atrophy, is the primary hormone therapy products at Warner Chilcott.",0.05018339306116104,0.006577464286237955,0.943239152431488,neutral,0.043605927377939224
8,2012-10-29 23:25:00,"The gastroenterology division primarily includes Asacol, approved for treating ulcerative colitis.",0.020300643518567085,0.0063606505282223225,0.9733387231826782,neutral,0.01393999345600605
9,2012-10-29 23:25:00,Asacol consists of two versions - Asacol 400 mg and Asacol HD (800 mg).,0.03290776535868645,0.007055543828755617,0.9600367546081543,neutral,0.025852221995592117
10,2012-10-29 23:25:00,"Currently, acne drug Doryx is the sole dermatological offering at Warner Chilcott.",0.013848673552274704,0.010746230371296406,0.9754051566123962,neutral,0.003102443180978298
11,2012-10-29 23:25:00,"Enablex, used for the treatment of overactive bladder, is the primary drug marketed under the urology segment.",0.03385540843009949,0.005385623313486576,0.9607589244842529,neutral,0.028469786047935486
12,2012-10-29 23:25:00,"Geographically, Warner Chilcott operates through two segments - North America and the Rest of World (ROW).",0.021583063527941704,0.006601853761821985,0.9718151092529297,neutral,0.014981210231781006
13,2012-10-29 23:25:00,"The North American segment includes the US, Canada and Puerto Rico.",0.014405789785087109,0.008337407372891903,0.9772567749023438,neutral,0.006068382412195206
14,2012-10-29 23:25:00,"With a significant part of its top line likely to be exposed to generic competition in the next few years, Warner Chilcott is looking towards cost-cutting initiatives to drive the bottom line.",0.890781044960022,0.027207253500819206,0.08201169967651367,positive,0.8635737895965576
15,2012-10-29 23:25:00,"Following the genericization of Actonel in Western Europe in late 2010, Warner Chilcott announced in April 2011 its decision to reorganize its operation in Western European nations, such as Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the UK.",0.5494819283485413,0.009943581186234951,0.44057443737983704,positive,0.5395383238792419
16,2012-10-29 23:25:00,"Following the implementation of the restructuring plan, the company's workforce has been trimmed by approximately 500 employees.",0.021862590685486794,0.966555655002594,0.011581662110984325,negative,-0.9446930885314941
17,2012-10-29 23:25:00,"Cost savings due to the restructuring led the company to lower its 2012 guidance for selling, general and administrative (SG&A) costs.",0.07083649933338165,0.7319875359535217,0.197175994515419,negative,-0.6611510515213013
18,2012-10-29 23:25:00,SG&A expenses for 2012 are now expected in the range of $775-$825 million (previous guidance: $800-$850 million).,0.02156173810362816,0.016063714399933815,0.9623745679855347,neutral,0.005498023703694344
19,2012-10-29 23:25:00,Research & development (R&D) expenses are now projected in the range of $100-$120 million (previous guidance: $110-$130 million).,0.01677095703780651,0.020423980429768562,0.9628050923347473,neutral,-0.0036530233919620514
20,2012-10-29 23:25:00,Warner Chilcott's 2012 adjusted earnings guidance is driven by reduced operating cost projection.,0.0195444505661726,0.9560561776161194,0.024399304762482643,negative,-0.936511754989624
21,2012-10-29 23:25:00,The company now expects adjusted earnings in the range of $3.55-$3.65 (previous guidance: $3.30-$3.40).,0.14462816715240479,0.007633967325091362,0.8477379083633423,neutral,0.13699419796466827
22,2012-10-29 23:25:00,We expect Warner Chilcott to achieve the guidance.,0.8047793507575989,0.01066632755100727,0.184554323554039,positive,0.794113039970398
23,2012-10-29 23:25:00,We are impressed by Warner Chilcott's acquisition of Procter & Gamble' s ( PG ) global branded prescription pharmaceutical business in 2009.,0.8938658833503723,0.012086901813745499,0.09404721111059189,positive,0.8817789554595947
24,2012-10-29 23:25:00,The acquisition has broadened Warner Chilcott's product portfolio significantly.,0.9403818845748901,0.01575499027967453,0.04386311396956444,positive,0.924626886844635
25,2012-10-29 23:25:00,Such prudent acquisitions should help Warner Chilcott to sustain growth since generic competition is likely to intensify further going forward.,0.9480531811714172,0.014708800241351128,0.037238046526908875,positive,0.9333443641662598
26,2012-10-29 23:25:00,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
27,2012-10-29 23:25:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
